WO2024059149A3 - Immunogenic coronavirus fusion proteins and related methods - Google Patents

Immunogenic coronavirus fusion proteins and related methods Download PDF

Info

Publication number
WO2024059149A3
WO2024059149A3 PCT/US2023/032660 US2023032660W WO2024059149A3 WO 2024059149 A3 WO2024059149 A3 WO 2024059149A3 US 2023032660 W US2023032660 W US 2023032660W WO 2024059149 A3 WO2024059149 A3 WO 2024059149A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
coronavirus
immunogenic
related methods
vectors
Prior art date
Application number
PCT/US2023/032660
Other languages
French (fr)
Other versions
WO2024059149A2 (en
Inventor
Abigail E. POWELL
Payton Anders-Benner WEIDENBACHER
Natalia FRIEDLAND
Mrinmoy SANYAL
Shaogeng Tang
Peter S. Kim
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Cz Biohub Sf, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University, Cz Biohub Sf, Llc filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO2024059149A2 publication Critical patent/WO2024059149A2/en
Publication of WO2024059149A3 publication Critical patent/WO2024059149A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Provided are fusion proteins including an amino acid sequence of an ectodomain of Spike protein of a coronavirus, such as SARS-CoV-2, joined to an amino acid sequence of a ferritin subunit polypeptide. Nanoparticles including such fusion proteins, with surface-exposed trimers of the ectodomain of the Spike protein of the coronavirus, are also provided. Also provided are nucleic acids and vectors encoding the fusion proteins, cells containing such nucleic acid and vectors, immunogenic compositions including the fusion proteins, the nanoparticles, or the vectors, as well as corresponding methods and kits.
PCT/US2023/032660 2022-09-14 2023-09-13 Immunogenic coronavirus fusion proteins and related methods WO2024059149A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263406366P 2022-09-14 2022-09-14
US63/406,366 2022-09-14
US202318043285A 2023-02-27 2023-02-27
US18/043,285 2023-02-27

Publications (2)

Publication Number Publication Date
WO2024059149A2 WO2024059149A2 (en) 2024-03-21
WO2024059149A3 true WO2024059149A3 (en) 2024-05-02

Family

ID=90275633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/032660 WO2024059149A2 (en) 2022-09-14 2023-09-13 Immunogenic coronavirus fusion proteins and related methods

Country Status (1)

Country Link
WO (1) WO2024059149A2 (en)

Also Published As

Publication number Publication date
WO2024059149A2 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
MX2023002413A (en) Immunogenic coronavirus fusion proteins and related methods.
HRP20200871T1 (en) Modified rsv f proteins and methods of their use
EP2829549A3 (en) Hybrid and tandem expression of neisserial derived proteins
CA2443365A1 (en) Methods for the recombinant production of antifusogenic peptides
WO2007149491A3 (en) Soluble stabilized trimeric hiv env proteins and uses thereof
WO2003052118A3 (en) Bgl4 beta-glucosidase and nucleic acids encoding the same
EP2460533A3 (en) Yeast-based therapeutic for chronic hepatitis C infection
WO2005118627A3 (en) Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use
CN105061581A (en) Preparation method for genetically coded holoprotein catenane
WO2006047680A3 (en) Lactobacillus acidophilus nucleic acids and uses thereof
WO2021207517A3 (en) Modified hr2 peptide inhibitors of coronavirus fusion
KR100484653B1 (en) Preparation method for the production of active and soluble proteins in prokaryotes and polycistronic vectors therefor
WO2002070647A3 (en) Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses
WO2024059149A3 (en) Immunogenic coronavirus fusion proteins and related methods
WO2004022697A3 (en) Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof
JPWO2020072821A5 (en)
ATE68827T1 (en) PREPARATION OF POLYPEPTIDES WITH AN ACID REAMIDE CARBOXY TERMINUS.
KR880002894A (en) Protein and DNA sequence used as a chemobacteremia wax
WO2023039534A3 (en) Compositions comprising a cas12i polypeptide and uses thereof
CY1106593T1 (en) A MYCOBACTERIUM TUBERCULOSIS CODING SEQUENCE FOR EXPRESSION OF HETEROLOGOUS PROTEINS
EP1570051A4 (en) Genetic constructs and compositions comprising rre and cte and uses thereof
WO2004056316A8 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2004016748A3 (en) Biotinylation of proteins
EP0345792A3 (en) Htlv-i / hiv-1 fusion proteins
WO2023212447A3 (en) Fusion protein for targeting recombinant proteins for degradation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23866163

Country of ref document: EP

Kind code of ref document: A2